Skip to main content

Month: September 2020

OMNIQ Corp. Awarded $1.8-Million Project from a Multi-billion Dollar Global Metal Solutions Provider

Project includes supply of mobile devices, software and services for the implementation of an advanced logistics program for product deliveriesAward follows over $7.5 million in orders from the Healthcare and Logistic Services verticals announced during Q3SALT LAKE CITY, Sept. 22, 2020 (GLOBE NEWSWIRE) — OMNIQ Corp. (OTCQB: OMQS) (“OMNIQ” or “the Company”), a provider of Supply Chain and Artificial Intelligence (AI)-based solutions, today announced that it has been awarded a project with a total value of approximately $1.8 million by a global metal solutions provider and one of the largest metals services companies in North America. The project consists of approximately $1.2 million for the supply of Android-based mobile computing devices with communication capabilities and approximately $0.6 million for software and services. It...

Continue reading

Origin Bank Gains Lending Efficiency and an Improved Customer Experience With nCino

WILMINGTON, N.C., Sept. 22, 2020 (GLOBE NEWSWIRE) — nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking and digital transformation solutions for the global financial services industry, today announced that $5.3 billion-asset Origin Bank has implemented the nCino Bank Operating System to create better efficiency in its loan origination process and a more streamlined client experience through enhanced digital engagement capabilities.Headquartered in Choudrant, Louisiana and serving communities throughout Louisiana, Texas and Mississippi, Origin Bank places a strong focus on client service. Origin recognized that in a competitive banking landscape with numerous options for clients to choose from, it needed a strong digital presence to meet existing and future clients’ needs and expectations. By implementing nCino’s Commercial Banking...

Continue reading

Healthcare Valuation Expert Todd Mello Joins FTI Consulting as a Senior Managing Director

WASHINGTON, Sept. 22, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced continued investment in its healthcare valuation capabilities with the appointment of Todd Mello as a Senior Managing Director and Leader of the Valuation Services group within the firm’s Health Solutions practice.Based in Brentwood, Tenn., Mr. Mello brings 30 years of valuation and transactions experience, 10 of which were spent in the managed care, physician practice management and investment banking fields.“Valuation is a complex process that requires a skillful blend of analysis, industry experience and well-founded judgment,” said Tim Renjilian, a Senior Managing Director in the Health Solutions practice at FTI Consulting. “Our Valuation Services team has assisted some of the largest healthcare systems, pharmaceutical companies and...

Continue reading

Auxly’s Subsidiary KGK Science Receives Research Licence to Conduct Product Palatability and Sensory Testing with Human Subjects

TORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”), a consumer packaged goods company in the cannabis products market, is thrilled to announce that its wholly owned subsidiary, KGK Science Inc. (“KGK”) has received its second Cannabis Research Licence from Health Canada pursuant to the Cannabis Act. This licence permits KGK to administer cannabis extracts, edible cannabis and cannabis topicals to human subjects for purposes of palatability and sensory testing at its clinical research facility located in London, Ontario.Sensory evaluation measures, analyzes and interprets the reaction of human subjects to products as perceived by the senses, it is an incredibly valuable tool in understanding and determining consumer preferences and the basis for those differences....

Continue reading

Genocea Announces FDA Acceptance of GEN-011 IND Application

CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) Application for GEN-011, an adoptive T cell therapy targeting neoantigens and designed to improve upon the limitations of TIL and TCR therapies. The IND allows Genocea to initiate a Phase 1/2a clinical study of GEN-011 in patients who have failed standard-of-care checkpoint inhibitor therapy. The trial will evaluate safety, T cell proliferation and persistence as well as clinical activity.“GEN-011 builds on the power of our ATLAS™ platform, as demonstrated in our GEN-009 clinical trial, to identify the relevant neoantigens which drive...

Continue reading

Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab

Key cognitive endpoints trending towards but did not reach statistical significance in early manifest population. Overall study does not meet pre-specified co-primary endpointsResults support continued development in Alzheimer’s disease and in mid-stage Huntington’s disease patients with greater cognitive deficitsCompany to host investor conference call today, September 22, at 8:30 a.m. EDTTo access the call and webcast, please click here.ROCHESTER, N.Y., Sept. 22, 2020 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced topline results from the early manifest treatment arm (Cohort B1, N=179) of the Phase 2 double-blind, placebo-controlled SIGNAL trial of its...

Continue reading

BridgeBio Pharma to Host Virtual R&D Day on September 29, 2020

PALO ALTO, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers, today announced that it will host its first R&D Day on Tuesday, September 29, at 8:30 am E.T.The virtual event will feature presentations from BridgeBio founder and CEO, Neil Kumar, Ph.D., senior scientists and physicians leading BridgeBio’s drug discovery and development programs, and top academic physicians and scientists from outside the company.The program will focus on BridgeBio’s drug engineering platform, its targeted oncology portfolio, and four highlighted programs with clinical data anticipated in the next 12-24 months – acoramidis (AG10, TTR stabilizer) for transthyretin amyloidosis, low-dose infigratinib (FGFR...

Continue reading

Art Angels Supports Restoration of Art Industry with Collection Sites COVID-19 Testing Services and Protocols

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) — QuestCap Inc. (“QuestCap” or the “Company”) (CSE:QSC; FRA:34C1) through its wholly-owned subsidiary, Collection Sites, LLC is working with Art Angels Gallery, Los Angeles, California to launch COVID-19 testing protocols to help safely return art exhibitions for artists and consumers. This event will feature world-renown artist Russell Young September 24th, 2020 in Beverly Hills, California.The COVID-19 testing and operating protocols have been developed by medical experts and QuestCap advisors, Dr. Glenn Copeland and Dr. Lawrence Steinman, and will help ensure the safety of employees, artists, and viewers. The testing consist of both digital temperature checks and rapid serology tests using...

Continue reading

Gold’n Futures enters into Letter of Intent with Argonaut Gold Inc.

TORONTO, Sept. 22, 2020 (GLOBE NEWSWIRE) — GOLD’N FUTURES MINERAL CORP. (CSE: FUTR) (FSE: G6M), (the “Company”), is pleased to announce that it has entered into a non-binding letter of intent with Argonaut Gold Inc. (“Argonaut”) to acquire up to a 90% interest in the Hercules – Elmhurst property (the “Property”) located 120 kilometers northeast of Thunder Bay, Ontario in the townships of Elmhurst and Rickaby, within the Thunder Bay North Mining District (the “LOI”).   The Property lies within an Archean greenstone belt that extends from the Longlac area in the east to Lake Nipigon in the west, a distance of some 130 kilometers. The property consists of 372 contiguous claim cells (6951 hectares).To date, the work completed on the Property forms an extensive database including reconnaissance grab samples; channel samples; a variety...

Continue reading

SYQH successfully logged into OTC

Boca Raton, FL, Sept. 22, 2020 (GLOBE NEWSWIRE) — SYQH acquired EVGI through reverse merger and acquisition.The assets of Liaoning Shuiyun Qinghe Rice Industry Co., LTD. (stock code: SYQH) will be loaded into the listed company in the form of reverse merger. The company will issue 1 billion shares and appoint Cui Weiming as the chairman and director and Chang Xu as the director.Founded in 2013, SYQH has been deeply engaged in the rice industry for more than a decade, and is a national enterprise integrating production and processing, chain sales and new retail. The company’s two brands, Shuiyun Qinghe and Shuiyun Daoxiang, have sold more than 100 series of products to more than 100 cities in China, and have deep cooperation with petrochina and Huilian. In addition to selling products, the company introduced food-related knowledge...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.